The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ILyAD (Indolent Lymphoma and Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy.
 
Michael Brady
No Relationships to Disclose
 
Myla S. Strawderman
No Relationships to Disclose
 
Christopher Flowers
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Celgene; Denovo Biopharma; Gilead Sciences; Karyopharm Therapeutics; OptumRx; Pharmacyclics/Janssen; Seagen; Spectrum Pharmaceuticals
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immune Design (Inst); Infinity Pharmaceuticals (Inst); Janssen Oncology (Inst); Onyx (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Genentech/Roche; Gilead Sciences
 
Brad S. Kahl
Consulting or Advisory Role - Abbvie; Acerta Pharma; ADC Therapeutics; Celgene; Cell Therapeutics; Genentech/Roche; Juno Therapeutics; Millennium; Pharmacyclics; Seagen
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Abbvie; Celgene; Genentech/Roche; Juno Therapeutics; Millennium; Seagen
 
John Paul Leonard
Consulting or Advisory Role - Abbvie; Celgene; Sutter Medical Group
Travel, Accommodations, Expenses - Juno Therapeutics
 
Loretta J. Nastoupil
Honoraria - Abbvie; Celgene; Genentech/Roche; Gilead Sciences; Novartis; Pharmacyclics; TG Therapeutics
Research Funding - Abbvie; Celgene; Genentech/Roche; Janssen Biotech; Karus Therapeutics; TG Therapeutics
 
Thomas E. Witzig
Stock and Other Ownership Interests - Valeant Pharmaceuticals International
Consulting or Advisory Role - Celgene; Seagen
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
 
Derick R. Peterson
Consulting or Advisory Role - Angle
Research Funding - Gilead Sciences (Inst); Zoll (Inst)
 
Jonathan W. Friedberg
Consulting or Advisory Role - Bayer
Research Funding - Kite, a Gilead company (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Roche